Osińska-Królak Mariola, Kurylak Andrzej, Wysocki Mariusz, Kurylak Danuta, Kindracka Aleksandra, Balcar-Boroń Anna
Katedry i Kliniki Pediatrii, Hematologii i Onkologii Akademii Medycznej w Bydgoszczy.
Wiad Lek. 2003;56(3-4):152-6.
The study has been evaluated an efficiency of preventive use of hematopoietic cytokines in children with neoplastic diseases. The analysed material consisted of 28 children with neoplastic diseases. They all had 148 incidents of chemotherapy-induced myelosuppression with prophylactic use of GM-CSF or G-CSF 5 micrograms/kg daily. The study showed that the prophylactic use of hematopoietic growth factors after the end of each chemotherapy course significantly shortens the duration of extreme neutropenia, the length of treatment of neutropenia-induced infections, the time of hospital care and decreases the delay between succeeding chemotherapy courses.